Discovery

IRF-5 antagonist

A discovery-stage small molecule targeting the intrinsically disordered transcription factor IRF-5 to dampen the interferon and inflammatory signalling that drives autoimmune disease.

Target
IRF-5
Modality
Small molecule
Indication
Autoimmune and inflammatory disease, including systemic lupus erythematosus
Stage
Discovery

Target

Interferon regulatory factor 5 (IRF-5) is a transcription factor with intrinsically disordered regions that switch its activity on downstream of innate immune signalling. Common IRF-5 variants are among the strongest genetic links to systemic lupus erythematosus and related autoimmune conditions, yet the protein presents no classical binding pocket for conventional design.

Approach

Peptone applies its Product Engine to characterise the conformational ensemble of IRF-5 and to search for binders that block the interactions it needs to activate inflammatory gene programmes. This extends the same disorder-first discovery work into immunology and inflammation.

Preclinical

As a discovery-stage example, work is focused on target validation and early hit finding against defined disordered regions of the protein.

Development Plan

This example program is at discovery, where hit-finding and target validation precede progression into a dedicated chemical series.

This is an illustrative example program used to demonstrate the pipeline layout. It does not represent an approved or actual Peptone program.